Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05680480 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Telitacicept in Lupus Nephritis

StatusUnknown
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 23, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Dec 2024 to Dec 2025 Completion date: Jan 2025 to Jan 2026 · Eligibility criteria expanded, about 16 wordsv4 Show 2 more changesShow less
    • Completion date: Jan 2025 to Jan 2026
    • Eligibility criteria expanded, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 2023 to Apr 17, 2023 · Site details revised at 45 of 45 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2023 to Apr 17, 2023
    • Site details revised at 45 of 45 sites
  4. Study title shortened, about 8 wordsv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
Trial Details
NCT Number NCT05680480
Lead Sponsor RemeGen Co., Ltd.
Conditions Lupus Nephritis
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov